Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 14/20 | 0.51 |
| ▸ | TACR3 | P29371 | 13/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200694 | 1.00 | TACR2 (0.51) | TACR2TACR3OPRM1TRPV4PDE10A | |
| SCHEMBL6200702 | 1.00 | TACR2 (0.51) | TACR2TACR3OPRM1TRPV4PDE10A | |
| SCHEMBL5733751 | 0.87 | TACR3 (0.62) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5945331 | 0.85 | TACR2 (0.67) | TACR2TACR3OPRM1TRPV4PDE10A | |
| SCHEMBL6852921 | 0.84 | TACR2 (0.53) | TACR2TACR3OPRM1TRPV4PDE10A | |
| SCHEMBL6857830 | 0.83 | TACR2 (0.55) | TACR2TACR3OPRM1TRPV4PDE10A | |
| Hydrochloric Acid SCHEMBL6851636 | 0.83 | TACR3 (0.52) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5635546 | 0.82 | TACR3 (0.76) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL8116231 | 0.82 | TACR3 (0.76) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL6848843 | 0.82 | TACR3 (0.58) | TACR2TACR3OPRM1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377567-B1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2005-12-21 | — | — | EP | claimed |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXOSMITHKLINE SPA | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNQ3, KCNK3, KCNK2 | TACR2 22/4885TACR3 45/4885OPRM1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.